Stage IIIA | Stage IIIB | Stage IIIC | P value | |
(n=317) | (n=18) | (n=655) | ||
Mean±SD | Mean n±SD | Mean±SD | ||
Age in years | 59.7±12.1 | 60.1±10.8 | 60.5±10.1 | 0.488 |
CA125 (IU/mL) | 109.7±289.9 | 152.6±230.0 | 108±460.9 | 0.319 |
Number of pelvic lymph nodes removed from patients undergoing PLND | 25.2±12.9 | 19.7±10.0 | 27.3±13.1 | 0.622 |
Number of para-aortic lymph nodes removed from patients undergoing PALND | 9.8±9.3 | 8.2±5.4 | 13.8±10.7 | <0.0001 |
n (%) | n (%) | n (%) | P value | |
Menopausal status | 0.877 | |||
Pre- | 53 (16.7) | 2 (1.1) | 88 (13.4) | |
Post- | 264 (83.3) | 16 (8.9) | 567 (86.6) | |
Type of surgery | 0.912 | |||
Laparotomy | 294 (92.8) | 17 (94.4) | 607 (92.7) | |
Laparoscopy | 23 (7.2) | 1 (5.6) | 48 (7.3) | |
Lymphadenectomy | <0.001 | |||
None | 144 (45.4) | 10 (55.6) | 0 | |
Pelvic | 25 (7.9) | 3 (16.6) | 167 (25.5) | |
Pelvic+para-aortic | 148 (46.7) | 5 (27.8) | 488 (74.5) | |
Residual tumor | 0.811 | |||
0 | 311 (98.2) | 18 (100) | 639 (97.5) | |
≤1 cm | 3 (0.9) | 0 | 10 (1.5) | |
>1 cm | 3 (0.9) | 0 | 6 (0.8) | |
Grade | 0.601 | |||
1 | 50 (15.8) | 3 (16.7) | 115 (17.6) | |
2–3 | 267 (84.2) | 15 (83.3) | 540 (82.4) | |
LVSI | <0.0001 | |||
Negative | 106 (33.4) | 5 (27.8) | 98 (15) | |
Positive | 168 (53) | 11 (61.1) | 529 (80.7) | |
Not known | 43 (13.6) | 2 (1.1) | 28 (4.3) | |
Peritoneal cytology | 0.002 | |||
Negative | 148 (46.7) | 10 (55.6) | 451 (68.8) | |
Positive | 45 (14.2) | 2 (1.1) | 67 (10.2) | |
Not performed | 124 (39.1) | 6 (33.3) | 137 (21) | |
MMI | 0.023 | |||
0 | 9 (2.8) | 0 | 0 | |
<50% | 94 (29.7) | 5 (27.8) | 150 (22.9) | |
≥50% | 171 (54) | 11 (61.1) | 496 (75.7) | |
Not known | 43 (13.5) | 2 (1.1) | 9 (1.4) | |
Cervical involvement | 0.211 | |||
No | 209 (65.9) | 9 (50) | 409 (62.4) | |
Yes | 108 (34.1) | 9 (50) | 246 (37.6) | |
Adjuvant treatment modality | <0.0001 | |||
None | 18 (5.7) | 1 (5.5) | 5 (0.7) | |
RT alone | 77 (24.3) | 3 (16.7) | 99 (15.1) | |
CT alone | 65 (20.5) 157 (49.5) | 7 (38.9) | 170 (25.9) | |
CRT | 7 (38.9) | 381 (58.2) | ||
CT regimen | 0.01 | |||
Taxol+carboplatin | 137 (43.1) | 7 (38.9) | 340 (51.9) | |
Others | 82 (25.9) | 7 (38.9) | 121 (18.4) | |
Not known | 98 (31) | 4 (22.2) | 195 (29.7) | |
Status | 0.815 | |||
Alive | 244 (77) | 13 (72.2) | 486 (74.2) | |
Dead | 73 (23) | 5 (27.8) | 169 (25.8) |
CRT, chemoradiation; CT, chemotherapy; LVSI, lymphovascular space invasion; MMI, myometrial invasion; PALND, para-aortic lymph node dissection; PLND, pelvic lymph node dissection; RT, radiotherapy.